© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Rubraca

FDA Approves Liquid Biopsy Test For Multiple Cancers and Biomarkers

The blood test identifies biomarkers that could make patients eligible for targeted therapies.

Rubraca

Male reproductive system

FDA Approves Rubraca for BRCA-Mutated Metastatic Prostate Cancer

More than 40% of people treated with the PARP inhibitor saw tumor shrinkage.

PARP Inhibitor Delays Pancreatic Cancer Recurrence

Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.

PARP Inhibitor Shows Promise for Advanced Prostate Cancer

Rubraca shrank tumors and lowered PSA levels in men with advanced prostate cancer.

FDA Approves Rubraca for Ovarian Cancer Maintenance Treatment

Study showed patients receiving rucaparib had significant improvement in progression-free survival.
3D rendering of the breast

New PARP Inhibitor Improves Survival in Women With Advanced Breast Cancer

Talazoparib may offer an additional option for women with BRCA gene mutations.
Advertisement

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.